Fermenta Biotech Ltd

Fermenta Biotech Ltd announced a revision in its credit ratings today, as detailed in a letter received from CARE Ratings Limited, and disseminated via BSE Limited and the National Stock Exchange of India Limited. CARE Ratings Limited has upgraded the ratings for Fermenta Biotech Limited’s Long-term bank facilities, enhanced from Rs 118.94 to Rs 166.73, from CARE BBB; Stable to CARE BBB+; Stable, and Short-term bank facilities from CARE A3+ to CARE A 2. The total facilities amount is Rs 172.98, encompassing both Long-term bank facilities and Short-term bank facilities, and this information is also available on the company’s website, www.fermentabiotech.com.

Fermenta Biotech Ltd share price softened by 1.97% to Rs 548.5 after the company's net profit tanked by 48.76% to Rs 9.53 crore, while revenue from operations slightly gained 0.20% to Rs 121.82 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, rising 4.63%. It has marginally improved by 0.56% over last one week and advanced by 13.27% in last one month while the market capitalization of Fermenta Biotech Ltd has inched up 0.32% and 93.10% in the same period respectively. Profit before tax (PBT) of Fermenta Biotech Ltd stood at Rs 14.69 crore in Q2 FY26, plunging by 47.70% year-on-year, and nosediving by 43.95% quarter-on-quarter. EBITDA came in at Rs 14 crore, crashing by 29.65% YoY and slipping 8.37% sequentially. Total expenses saw a slight increase of 2.13% to Rs 108.96 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 38.75 crore, posting a minor increase of 4.33% YoY, while employee benefits expense was at Rs 23.01 crore, expanding by 7.88% YoY. For the TTM ended FY26, revenue from operations improved 11.92% to Rs 525.43 crore, while net profit eased 8.05% to Rs 70.25 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 9446% to Rs 77.45 crore, and PBT registered a growth of 15.20% to Rs 95.86 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 92.83 crore in FY26, as against Rs 40.9 crore in FY25. Fermenta Biotech Ltd rallied 58.48% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

Fermenta Biotech Limited announced today, August 4, 2026, the listing of its 2,94,30,987 equity shares on the National Stock Exchange of India Limited (NSE) under the symbol FERMENTA and ISIN INE225B01021, in addition to its existing listing on the BSE under Scrip Code 506414. The company, one of the world's largest manufacturers of Vitamin D3 API, commemorated the milestone with a bell-ringing event at the NSE’s Exchange Plaza, and Managing Director Prashant Nagre stated the listing reflects the company’s growth and expanding investor interest.

Fermenta Biotech Limited will hold a board meeting on August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, both standalone and consolidated, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. Trading in the company’s securities will be closed for directors, promoters, insiders, designated persons, their immediate relatives, auditors, and other connected persons from July 1, 2026, until 48 hours after the financial results are declared.

The approval enables Indian food and supplement manufacturers to use VITADEE Green in fortified foods, beverages, dietary supplements and nutraceutical products. The company said the approval opens up India's large consumer market for its plant-based Vitamin D3 solution and reinforces its position in science-backed Vitamin D3 products. Fermenta added that the product is protected by an Indian process patent and is developed and manufactured in India. Managing director Prashant Nagre said the approval will allow the company to address the country's widespread Vitamin D deficiency by offering a sustainable, scalable and affordable plant-based Vitamin D3 solution. He added that VITADEE Green supports the government's Make in India initiative by providing a domestically manufactured alternative for Indian formulators. Fermenta Biotech said the approval also provides vegetarian consumers with access to a plant-based Vitamin D3 option and supports the broader objective of addressing Vitamin D deficiency through food fortification. Fermenta Biotech manufactures nutritional ingredients, active pharmaceutical ingredients (APIs), intermediates and nutritional premixes, while also offering green chemistry and environmental solutions. The company operates manufacturing facilities in Himachal Pradesh, Gujarat and Andhra Pradesh, supported by an R&D centre in Thane, and serves more than 400 customers across over 60 countries. On a consolidated basis, Fermenta Biotech's net profit declined 44.20% to Rs 19.19 crore while net sales declined 13.06% to Rs 121.58 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live

Fermenta Biotech announced that its Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green') has received approval from the Food Safety and Standards Authority of India (FSSAI) for use as an ingredient in Health Supplements, Nutraceuticals and Food Products. The approval allows Indian food and supplement manufacturers to use VITADEE Green' in fortified staple foods, food and beverages, dietary supplements and nutraceuticals, addressing one of the most pressing gaps in the country's nutritional landscape. Studies estimate that a large percentage of the Indian population has suboptimal Vitamin D levels, a deficiency increasingly linked to urbanisation, indoor lifestyles and limited sun exposure despite the country's geography.

Fermenta Biotech Ltd gained 3.48% today to trade at Rs 364. The BSE Healthcare index is up 0.27% to quote at 48662.27. The index is up 2.48 % over last one month. Among the other constituents of the index, Viyash Scientific Ltd increased 3.4% and IOL Chemicals & Pharmaceuticals Ltd added 2.97% on the day. The BSE Healthcare index went up 12.87 % over last one year compared to the 7.1% fall in benchmark SENSEX. Fermenta Biotech Ltd has added 20.53% over last one month compared to 2.48% gain in BSE Healthcare index and 0.34% drop in the SENSEX. On the BSE, 3231 shares were traded in the counter so far compared with average daily volumes of 11042 shares in the past one month. The stock hit a record high of Rs 399 on 14 Jul 2025. The stock hit a 52-week low of Rs 256.4 on 05 Dec 2025.Powered by Capital Market - Live

Fermenta Biotech announced that the 74th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Fermenta Biotech announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 3.75 per equity Share (i.e. 75%) , subject to the approval of the shareholders.

Net profit of Fermenta Biotech declined 44.20% to Rs 19.19 crore in the quarter ended March 2026 as against Rs 34.39 crore during the previous quarter ended March 2025. Sales declined 13.06% to Rs 121.58 crore in the quarter ended March 2026 as against Rs 139.85 crore during the previous quarter ended March 2025. For the full year,net profit declined 6.62% to Rs 71.77 crore in the year ended March 2026 as against Rs 76.86 crore during the previous year ended March 2025. Sales rose 11.92% to Rs 525.43 crore in the year ended March 2026 as against Rs 469.48 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales121.58139.85 -13 525.43469.48 12 OPM %16.4526.42 -19.0023.39 - PBDT22.2537.85 -41 110.68107.43 3 PBT17.1431.98 -46 88.9883.21 7 NP19.1934.39 -44 71.7776.86 -7 Powered by Capital Market - Live